Ascelia Pharma AB (publ) (ACE) - Total Liabilities
Based on the latest financial reports, Ascelia Pharma AB (publ) (ACE) has total liabilities worth Skr22.01 Million SEK (≈ $2.37 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ascelia Pharma AB (publ) - Total Liabilities Trend (2016–2024)
This chart illustrates how Ascelia Pharma AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. See ACE current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Ascelia Pharma AB (publ) Competitors by Total Liabilities
The table below lists competitors of Ascelia Pharma AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
HY Electronic Cayman Ltd
TW:6573
|
Taiwan | NT$915.91 Million |
|
Lohakit Metal Public Company Limited
BK:LHK
|
Thailand | ฿425.43 Million |
|
InkTec Co. Ltd
KQ:049550
|
Korea | ₩79.82 Billion |
|
ALANDEQGRP FPO
AU:AEG
|
Australia | AU$3.09 Million |
|
LORDS CHLORO ALKALI ORD T (BSE)
NSE:LORDSCHLO
|
India | Rs2.36 Billion |
|
Persimmon PLC
LSE:PSN
|
UK | GBX1.70 Billion |
|
Firetail Resources Ltd
AU:FTL
|
Australia | AU$958.84K |
|
NH SPAC 5
KQ:215790
|
Korea | ₩34.35 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Ascelia Pharma AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ACE market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.19 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ascelia Pharma AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ascelia Pharma AB (publ) (2016–2024)
The table below shows the annual total liabilities of Ascelia Pharma AB (publ) from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr61.98 Million ≈ $6.67 Million |
+386.32% |
| 2023-12-31 | Skr12.74 Million ≈ $1.37 Million |
-66.21% |
| 2022-12-31 | Skr37.71 Million ≈ $4.06 Million |
+46.97% |
| 2021-12-31 | Skr25.66 Million ≈ $2.76 Million |
+32.82% |
| 2020-12-31 | Skr19.32 Million ≈ $2.08 Million |
+46.75% |
| 2019-12-31 | Skr13.16 Million ≈ $1.42 Million |
+16.03% |
| 2018-12-31 | Skr11.35 Million ≈ $1.22 Million |
+156.73% |
| 2017-12-31 | Skr4.42 Million ≈ $475.55K |
+58.33% |
| 2016-12-31 | Skr2.79 Million ≈ $300.36K |
-- |
About Ascelia Pharma AB (publ)
Ascelia Pharma AB (publ), a biotech company, develops identifies, develops, and commercializes novel drugs to treat orphan oncology treatments in Sweden. It develops Orviglance, a novel non-gadolinium diagnostic drug, which is in Phase 3 clinical trial for use in MRI-scans of the liver; and Oncoral, a novel oral irinotecan chemotherapy tablet, that is in Phase 2 clinical trial for the treatment o… Read more